{
    "clinical_study": {
        "@rank": "107502", 
        "arm_group": [
            {
                "arm_group_label": "Ketorolac trometamol 0.45%", 
                "arm_group_type": "Experimental", 
                "description": "Ketorolac trometamol 0.45% associated with carboxymethylcellulose  eye drops (Acular CMC\u00ae, Allergan, Irvine, USA) qid for 7 days."
            }, 
            {
                "arm_group_label": "Artificial tears", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Preservative free artificial tears (Optive UD\u00ae, Allergan, Irvine, USA) qid for 7 days."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the evolution of the symptoms of acute viral\n      conjunctivitis using preservative free ketorolac trometamol 0.45% associated with\n      carboxymethylcellulose compared with isolated use of preservative-free artificial tears."
        }, 
        "brief_title": "Artificial Tears Versus Preservative Free Ketorolac Trometamol 0.45% for Acute Viral Conjunctivitis", 
        "completion_date": {
            "#text": "March 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Conjunctivitis, Viral", 
        "condition_browse": {
            "mesh_term": [
                "Conjunctivitis", 
                "Conjunctivitis, Viral"
            ]
        }, 
        "detailed_description": {
            "textblock": "The purpose of this study is to evaluate the evolution of the symptoms of acute viral\n      conjunctivitis using preservative free ketorolac trometamol 0.45% associated with\n      carboxymethylcellulose compared with isolated use of preservative-free artificial tears. A\n      randomized double-masked study will include 60 patients divided into two groups: Group 1:\n      using a formulation of ketorolac tromethamine 0.45% associated with carboxymethylcellulose\n      (Acular CMC\u00ae, Allergan, Irvine, USA) and Group 0: using artificial tears (Optive UD\u00ae,\n      Allergan, Irvine, USA), both drugs without preservatives."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Acute conjunctivitis (unilateral or bilateral) for less than two weeks,\n\n          -  Signs and symptoms consistent with viral conjunctivitis and at least one of the\n             following: preauricular lymphadenopathy, upper tract respiratory infection or recent\n             contact with someone with conjunctivitis\n\n        Exclusion Criteria:\n\n          -  pregnant women\n\n          -  allergies to non-steroidal anti-inflammatories\n\n          -  history of seasonal allergic conjunctivitis\n\n          -  contact lens wearers\n\n          -  history of ocular herpes infection\n\n          -  blepharitis\n\n          -  severe dry eye\n\n          -  purulent discharge\n\n          -  defects in the corneal epithelium"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01799863", 
            "org_study_id": "FAV011_12"
        }, 
        "intervention": [
            {
                "arm_group_label": "Ketorolac trometamol 0.45%", 
                "intervention_name": "Ketorolac trometamol 0.45% with carboxymethylcellulose", 
                "intervention_type": "Drug", 
                "other_name": "Acular CMC\u00ae, Allergan, Irvine, USA"
            }, 
            {
                "arm_group_label": "Artificial tears", 
                "intervention_name": "Preservative free artificial tear", 
                "intervention_type": "Drug", 
                "other_name": "Optive UD\u00ae, Allergan, Irvine, USA"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Carboxymethylcellulose Sodium", 
                "Ketorolac", 
                "Ketorolac Tromethamine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Conjunctivitis, Viral", 
            "Ketorolac", 
            "Artificial tears"
        ], 
        "lastchanged_date": "February 25, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Recife", 
                    "country": "Brazil", 
                    "state": "Pernambuco", 
                    "zip": "50070040"
                }, 
                "name": "Funda\u00e7\u00e3o Altino Ventura"
            }
        }, 
        "location_countries": {
            "country": "Brazil"
        }, 
        "number_of_arms": "2", 
        "official_title": "Artificial Tears Versus Preservative Free Ketorolac Trometamol 0.45% for Treatment of Acute Viral Conjunctivitis", 
        "overall_official": [
            {
                "affiliation": "Funda\u00e7\u00e3o Altino Ventura", 
                "last_name": "Adriana Falc\u00e3o, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Funda\u00e7\u00e3o Altino Ventura", 
                "last_name": "Lucio Maranh\u00e3o, MD", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "Brazil: National Committee of Ethics in Research", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "March 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "General ocular discomfort, itching, foreign body sensation, tearing, eye redness and eyelid edema. Symptoms will be graded as 0 (absence), I (mild), II (moderate) and III (severe).", 
                "measure": "Change in ocular symptoms from baseline to treatment day 7", 
                "safety_issue": "No", 
                "time_frame": "7 days"
            }, 
            {
                "description": "The clinical examination will consist of slit-lamp examination of the anterior segment. Four signs will be assessed: conjunctival hyperemia, chemosis, secretion and follicles in lower tarsal conjunctiva. The signs will be classified as 0 (absence), I (mild), II (moderate), III (severe)", 
                "measure": "Change in ocular signs from baseline to treatment day 7", 
                "safety_issue": "No", 
                "time_frame": "7 days"
            }
        ], 
        "reference": [
            {
                "PMID": "10919900", 
                "citation": "Shiuey Y, Ambati BK, Adamis AP. A randomized, double-masked trial of topical ketorolac versus artificial tears for treatment of viral conjunctivitis. Ophthalmology. 2000 Aug;107(8):1512-7."
            }, 
            {
                "PMID": "16527227", 
                "citation": "Toker MI, Erdem H, Erdogan H, Arici MK, Topalkara A, Arslan OS, Pahsa A. The effects of topical ketorolac and indomethacin on measles conjunctivitis: randomized controlled trial. Am J Ophthalmol. 2006 May;141(5):902-905. Epub 2006 Mar 9."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01799863"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Funda\u00e7\u00e3o Altino Ventura", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Funda\u00e7\u00e3o Altino Ventura", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }
}